VIVUS (NASDAQ:VVUS) Trading 0.5% Higher
VIVUS, Inc. (NASDAQ:VVUS) shares traded up 0.5% during trading on Wednesday . The stock traded as high as $4.40 and last traded at $3.94, 4,291 shares traded hands during mid-day trading. A decline of 79% from the average session volume of 20,522 shares. The stock had previously closed at $3.92.
Separately, ValuEngine raised shares of VIVUS from a “sell” rating to a “hold” rating in a report on Thursday, August 1st.
The company’s fifty day simple moving average is $3.45 and its 200 day simple moving average is $3.95. The stock has a market capitalization of $34.16 million, a P/E ratio of -1.14 and a beta of 1.83.
Several institutional investors have recently bought and sold shares of the company. BlackRock Inc. raised its position in shares of VIVUS by 6.6% during the 2nd quarter. BlackRock Inc. now owns 220,707 shares of the biopharmaceutical company’s stock valued at $843,000 after buying an additional 13,572 shares in the last quarter. Spark Investment Management LLC purchased a new stake in shares of VIVUS during the 1st quarter valued at $98,000. Alambic Investment Management L.P. purchased a new stake in shares of VIVUS during the 1st quarter valued at $51,000. Finally, Sterling Investment Advisors Ltd. purchased a new stake in shares of VIVUS during the 1st quarter valued at $42,000. Hedge funds and other institutional investors own 15.10% of the company’s stock.
About VIVUS (NASDAQ:VVUS)
VIVUS, Inc operates as a specialty pharmaceutical company primarily in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body-mass index of 30 or greater (obese patients) or 27 or greater (overweight patients) in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus, or high cholesterol.
Featured Story: Municipal Bonds
Receive News & Ratings for VIVUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VIVUS and related companies with MarketBeat.com's FREE daily email newsletter.